VivoSeq
47

Pipeline Programs

12

Active Trials

21

Companies Involved

Hernia is a moderately active landscape with 47 programs across 21 companies. The most active players are TLC Biopharmaceuticals, Inc., Mononuclear Therapeutics Ltd., Gynecologic Oncology Group. 13 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

27/100

Mech. Concentration

20/100

Completion Rate

81/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

56

clinical trials

Completed29 · 52%
Unknown status8 · 14%
Recruiting7 · 13%
Terminated4 · 7%
Active, not recruiting3 · 5%
Withdrawn3 · 5%
Other2 · 4%

Trial Activity

56 trials

Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs
Active, not recruiting··Phase 1·NCT05177991·200 enrolled
Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia
Not yet recruiting··Phase 4·NCT07247240·40 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)